The FOXG1 Research Foundation is thrilled to share a recap of our participation at the 2024 American Society of Gene and Cell Therapy (ASGCT) conference in Baltimore. This conference marked a significant milestone for our foundation, truly a "coming out party" to Pharma for our commitment to developing a gene therapy for FOXG1 syndrome.

The FOXG1 Research Foundation is happy to share our 2024 Q2 update on FOXG1 Research and Development from our Chief Scientific Officer, Dr. Soo-Kyung Lee and our Chief Drug Development Officer, Dr. Gai Ayalon.